Excess deaths associated with the two pandemics are in the same ballpark during New York City peaks.
The excess mortality in New York City during the peak of the 1918 flu pandemic and the excess mortality during the early months of the COVID-19 pandemic were similar, according to a brief research report published in today’s JAMA Network Open.
During the peak months of the 1918 flu epidemic, there were 31,589 deaths from all causes among the city’s 5.5 million residents, according to Jeremy Samuel Faust, M.D., M.S., at Brigham and Women’s Hospital, and his colleagues, Zhenqiu Lin, Ph.D., at Yale-New Haven Hospital, and Carlos de Rio, M.D., at the Emory University School of Medicine.
That works out to 287.17 deaths per 100,000 person-months.
During the early phase of the COVID-19 outbreak in the city, between March 11 and May 11, there were 33,465 deaths from all causes among the 8.3 million residents, Faust and his colleagues calculated
That works out to 202.08 deaths per 100,000 person-months, so a lower proportion than the one for the 1918 flu epidemic peak period but still in the same ballpark.
“These findings suggest that the mortality associated with COVID-19 during the early phase of the New York City outbreak was comparable to the peak mortality observed during the 1918 H1N1 influence epidemic,” the researchers wrote.
But when Faust and his colleagues compared the peak periods of the two pandemics in New York City to baseline mortality rates in the preceding years, they found that the COVID-19 spike is higher relative to the 1918 spike. The peak mortality of the 1918 flu was about three times higher than the mortality in preceding years, whereas the peak COVID-19 mortality was four times higher than in the preceding years.
The research team used CDC data from 1914-18 to calculate the the figures for the 1918 flu pandemic. To developed the numbers for COVID-19, they sifted through data from the New York City Department of Health and Mental Hygiene and the U.S. Census Bureau.
Faust, Lin and de Rio said their study can’t address the question whether the 1918 H1N1 flu virus was more or less “naturally” virulent — that is, more or less likely to cause death or harm — than SARS-CoV-2, the virus that causes COVID-19. To make that comparison, they said, you’d have to know how many COVID-19 deaths have been averted by 21st century treatment advances that didn’t exist in the early 20th century.
The estimates vary, but the CDC says that the 1918 flu pandemic caused at least 50 million deaths worldwide and 675,000 deaths in the U.S. Using those figures, about 1.3% of the 1918 flu pandemic deaths were American deaths.
The COVID-19 count on the John Hopkins Coronavirus Resource Center this morning was 750,371 deaths worldwide and 166,118 in the U.S. Using that tally, 22% of the COVID-19 deaths so far have been American deaths.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 28th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More